Who is sponsoring NCT01880411?

NCT01880411 is sponsored by HealthBanks Biotech Co., Ltd..

What condition does NCT01880411 study?

NCT01880411 studies Cervical Intraepithelial Neoplasia.

What drugs are being tested in NCT01880411?

Interventions: PEK Fusion Protein Vaccine.

What is the status of NCT01880411?

NCT01880411 is currently UNKNOWN.

Last reviewed 2013-06-14 · How we verify

Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity of a Three Dose Regimen of Escalating Doses of PEK Fusion Protein Vaccine (PEK + GPI-0100) in Patients With LSIL or HSIL

NCT01880411 Phase 1 UNKNOWN

Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity of a Three Dose Regimen of Escalating Doses of PEK Fusion Protein Vaccine in Women with LSIL or HSIL. PEK fusion protein vaccine (PEK + GPI-0100) is safe and well tolerated in patients with low-grade squamous intraepithelial lesions (LSIL) or high grade squamous intraepithelial lesions (HSIL) of the cervix and induces a measurable immune response.

Details

Lead sponsor	HealthBanks Biotech Co., Ltd.
Phase	Phase 1
Status	UNKNOWN
Enrolment	15
Start date	2013-06
Completion	2014-06

Conditions

Cervical Intraepithelial Neoplasia

Interventions

PEK Fusion Protein Vaccine

Primary outcomes

Number of participants with adverse events. — 6 Months